Dove Mild Cleanser

PreclinicalSmall molecule

UUniversity of Michigan

Dove Mild Cleanser is one of 10 small molecule programs targeting Tolerance. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToleranceCompleted

TolerancePreclinical

Completed

Competition

Competitive Landscape

12 competitors in Tolerance

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

6 2

Fludara

Sanofi

Phase 2

2 3

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 4

Avigan

AAppili Therapeutics Inc.

Phase 2

2 5

Siplizumab

UUniversity of Alabama at Birmingham

Phase 2

1 6

Experimental

Biogen

Preclinical

1 7

Levo-Dromoran

VValeant Pharmaceuticals

Preclinical

1 8

Tazorac

FFougera Pharmaceuticals Inc.

Preclinical

1 9

Oxytocin Treatment

UUniversity of Electronic Science and Technology of China

Preclinical

1 10

Dove Mild Cleanser

UUniversity of Michigan

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tolerance1 trial

The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance

Completed·UUniversity of Michigan·N/A·NCT00440024·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dove Mild Cleanser. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dove Mild Cleanser compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dove Mild Cleanser. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Michigan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Michigan

Dove Mild Cleanser

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tolerance1 trial

References

Drug Info

Quick Facts

Related News